CClinicalTrials.gg
CompletedNCT00431483Updated Sep 26, 2013

Clinical and Economic Impact of Interventions by a Clinical Pharmacist on Antibiotic Use on Surgical Wards

An interventional study of pharmaceutical consulting in Bacterial Infections, sponsored by Ludwig-Maximilians - University of Munich. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-09-26.

Sponsored by Ludwig-Maximilians - University of Munich · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
779
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to establish the impact of a pharmacist's recommendations regarding choice, dosing and duration of antibiotic therapy on quality and cost of antibiotic treatment on surgical wards.

Read the detailed description

Inappropriate or incorrect use of antibacterials exerts selection pressure on pathogens potentiating emergence of resistance, puts patients at risk for unnecessary adverse drug reactions and potentially prolongs the length of stay in hospital thus increasing healthcare costs.

In an effort to improve the quality of antibiotic drug therapy on surgical wards of a large university hospital, specific consulting by a clinical pharmacist was established.

The objective of this study is to assess the impact of pharmaceutical consulting on the quality and costs of antibiotic use in surgical wards.

Comparison:

Within a control period the current pattern of antibiotic use is monitored. During the intervention period, the impact of the interventions made by the clinical pharmacist on antibiotic use is examined. One ward serves as a parallel control group; no intervention is being made on this ward throughout this study.

02

Conditions studied

  • Bacterial Infections

Browse trials for

Keywords

  • antibacterial agents
  • surgery
  • pharmacist
  • economics, pharmaceutical
03

In context

Bacterial Infections

658 studies on the registry are indexed under Bacterial Infections; 100 are open to participants now.

This study's enrollment of 779 is above the median of 84 across 405 interventional studies indexed under Bacterial Infections.

Browse Bacterial Infections studies →

Lead sponsor

Ludwig-Maximilians - University of Munich is the lead sponsor of 218 studies on the registry; 29 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • female and male patients receiving antibiotics for a proven or suspected infection on designated surgical wards

Exclusion criteria

Exclusion Criteria:

  • patients under 18
  • patients unable or unwilling to consent to their data being evaluated
  • patients receiving antibiotics perioperatively as prophylaxis
  • patients receiving antibiotics for less than 48hrs
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
779 participants (actual)

Study arms

  • Other
    Pharmaceutical counseling

    Behavioral: pharmaceutical consulting

Interventions

  • Behavioralpharmaceutical consulting

    to measure if information and advice by a pharmacist has an impact on quality and quantity of prescribed antibacterials

06

What researchers measure

Primary outcomes

  1. overall duration of antibiotic therapy during study period

    Time frame: Feb 2008

Secondary outcomes

  1. iv to oral switch

    number of courses of iv antibiotics switched to oral antibiotics; duration of iv treatment

    Time frame: Feb 2008

  2. compliance of treatment with hospital formulary for antibiotic therapy

    Time frame: Feb 2008

  3. cost of antibiotic therapy

    Time frame: Feb 2008

  4. number and duration of therapy with antibiotics with redundant spectra

    Time frame: Feb 2008

07

Study locations

1 site
  • Luwig Maximilians University - Klinikum Grosshadern
    Munich, Bavaria 81377, Germany
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 26, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00431483
Lead sponsor
Ludwig-Maximilians - University of Munich
Responsible party
Alexandra Weber (Pharmacist, Ludwig-Maximilians - University of Munich) — Principal investigator
First posted
Feb 5, 2007
Start date
Feb 2007
Primary completion
Feb 2008
Completion
Feb 2008
Last update
Sep 26, 2013

Study contacts

Karl-Walter Jauch, Prof. Dr.
study director · Klinikum Grosshadern

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion